<DOC>
	<DOC>NCT00221195</DOC>
	<brief_summary>The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.</brief_summary>
	<brief_title>Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>hemophilia A, any severity, with documented history of hightiter inhibitor (&gt;5BU); current use of bypassing agents (PCCs, aPCCs or rFVIIa) for treatment of bleeds; &gt;/= 6 bleeds requiring bypassing therapy in the previous 6 months concomitant immune tolerance therapy; clinically symptomatic liver disease, platelet count less than 100,000</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>